Mendus secures third shareholder loan from Van Herk Investments

17 May 2023
www.globenewswire.com
Immunotherapy
Mendus secures third shareholder loan from Van Herk Investments
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a third loan from its largest shareholder Van Herk Investments (“VHI”). The loan in the amount of SEK 15M carries a 6% annual interest rate. It is part of the total SEK 50M financing facility put in place between Mendus and VHI on August 26, 2022. The end date of this loan is 31 December, 2023. As part of the new loan agreement, the end dates of the other loans already drawn have also been amended to 31 December 2023.
With today’s transaction, Mendus has now drawn the full amount of SEK 50M put in place as financing facility between Mendus and VHI on August 26, 2022.
For further information regarding the financing arrangement in place with VHI and earlier loans drawn, please refer to the press releases published on 26 August 2022, 26 October, and 7 March 2023.
This information is such information that Mendus AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (No. 596/2014). The information was submitted for publication through the agency of the contact persons set out below on May 17, 2023, at 14:00 CET.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Corey Davis
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
230517_Mendus_VHI_3rd_Tranche_ENG


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.